University of Maryland, Baltimore BioPark Signs Gliknik Inc. First Tenant in Its BioInnovation Center in Building Two
Published: Jan 10, 2008
BALTIMORE, Jan. 9 /PRNewswire-USNewswire/ -- The University of Maryland, Baltimore (UMB) BioPark today announced that Gliknik Inc., a Baltimore-based biotech company, is the first tenant in the BioInnovation Center, located in UMB BioPark's Building Two.
Gliknik is creating novel biotechnology drugs for autoimmune diseases and cancer, the foundation of which resulted principally from the labs of Dr. Scott Strome, Professor and Chairman of the Department of Otorhinolarynogology, University of Maryland School of Medicine.
The UMB BioPark's BioInnovation Center consists of 8,500 square feet of space, including 10 wet labs, five office suites, a shared conference room, kitchenette, and equipment room, which provide bioscience companies affordable, pre-built wet lab and office space through short-term leases. Gliknik will reside in two labs of the Center upon its build-out completion, expected by March.
"We are thrilled to welcome the first BioInnovation Center tenant," said Jim Hughes, president of the UMB BioPark. "This unique space will fill a critical need in the Baltimore region and Gliknik is just the first of many innovative life sciences companies that will benefit from its flexibility and cost-effective structure."
"Gliknik is pleased to be both a licensee of UMB technology and an early resident of the BioInnovation Center at the UMB BioPark," said David S. Block, President and CEO, Gliknik Inc. "We have enjoyed working closely with UMB and Wexford Science + Technology. Gliknik looks forward to bringing novel drugs into clinical trials with the goal of helping patients with autoimmune diseases and cancer." Gliknik was represented in this transaction by Grubb & Ellis.
Gliknik Inc. is a privately owned corporation committed to the discovery and development of novel biomolecules for autoimmune diseases and cancer. The company capitalizes on its expertise in immunology and tumor immunology. Gliknik's lead compounds are novel T cell vaccines in clinical safety studies. Gliknik also has created recombinant mimetics of intravenous immune globulin and recombinant mimetics of monoclonal antibodies. For further information, please visit www.gliknik.com.
About Wexford Science+Technology
A wholly owned subsidiary of Wexford Equities, LLC, Wexford Science+Technology is a privately held real estate investment and development company based in Baltimore, MD. With a team of real estate, finance and engineering experts, Wexford is devoted to developing innovative real estate solutions that inspire creativity and advance new technologies. For more information, please visit www.wexfordequities.com.
About UMB BioPark
The University of Maryland, Baltimore BioPark offers sophisticated laboratory and office space for early-stage to mature bioscience companies. To date, the UMB BioPark includes 360,000 square feet in two multi tenant buildings and one 638 space parking garage. The project has created 200 jobs and $128 million in capital investment. The BioPark was named by the Association of University Research Parks as the best emerging research park on the year in October 2007. For more information, please visit www.umbbiopark.com
CONTACT: Ashby Heath, +1-410-727-6855 or email@example.com, for UMB
Web site: www.gliknik.com/